research papers
Structural and functional analysis of betaine aldehyde dehydrogenase from Staphylococcus aureus
aDepartment of Biochemistry and Molecular Genetics, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA, bCenter for Structural Genomics of Infectious Diseases (CSGID), Chicago, IL 60611, USA, cBiosensor Tools LLC, Salt Lake City, UT 84103, USA, and dDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, Ontario M5S 3E5, Canada
*Correspondence e-mail: wf-anderson@northwestern.edu
When exposed to high Staphylococcus aureus (MRSA) restores its growth and establishes a new by accumulating the osmoprotectant metabolite betaine. Effective osmoregulation has also been implicated in the acquirement of a profound antibiotic resistance by MRSA. Betaine can be obtained from the bacterial habitat or produced intracellularly from choline via the toxic betaine aldehyde (BA) employing the choline dehydrogenase and betaine aldehyde dehydrogenase (BADH) enzymes. Here, it is shown that the putative betaine aldehyde dehydrogenase SACOL2628 from the early MRSA isolate COL (SaBADH) utilizes betaine aldehyde as the primary substrate and nicotinamide adenine dinucleotide (NAD+) as the cofactor. Surface plasmon resonance experiments revealed that the affinity of NAD+, NADH and BA for SaBADH is affected by temperature, pH and buffer composition. Five crystal structures of the wild type and three structures of the Gly234Ser mutant of SaBADH in the apo and holo forms provide details of the molecular mechanisms of activity and substrate specificity/inhibition of this enzyme.
methicillin-resistantKeywords: betaine aldehyde dehydrogenase; Staphylococcus aureus; structural genomics; high-throughput approach; infectious diseases.
PDB references: betaine aldehyde dehydrogenase, 4mpb; complex with NAD+, 4mpy; complex with NAD+ with BME-free Cys289, 4nea; with BME-free Cys289, 4nu9; with BME-modified Cys289 and PEG molecule in active site, 4qto; G234S mutant, in complex with NAD+ with BME-free Cys289, 4qn2; G234S mutant, with BME-modified Cys289, 4q92; G234S mutant, with BME-free sulfinic acid form of Cys289, 4qje
1. Introduction
Staphylococcus aureus commensally colonizes the skin, mucous membranes and gastrointestinal tract of healthy humans and causes mild to severe infections in hospital settings (DeLeo & Chambers, 2009; Eady & Cove, 2003; Jevons, 1961; Moellering, 2012; Scheffler et al., 2013; Wendlandt et al., 2013). Methicillin-resistant S. aureus (MRSA) is the most dangerous strain and its diverse antibiotic resistance is a major global problem (Paulsen et al., 1997; Cosgrove et al., 2006; Wenzel, 2004; Abboud & Waisbren, 1959; Walsh, 1999; Otto, 2010; Gill et al., 2005). Community-associated MRSA infections are also on the rise (Moellering, 2012; Wendlandt et al., 2013) along with reports of animal/livestock-associated MRSA (Fluit, 2012; Armand-Lefevre et al., 2005; Cuny et al., 2010; Pantosti, 2012), suggesting that MRSA is a food-borne pathogen (Kluytmans, 2010).
Food-preservation techniques, including the reduction of water activity, have routinely been used to suppress the growth of food-related pathogens (Archer, 1996; McDowell, 2004; McMahon et al., 2007). However, they have also been implicated in triggering the development and spread of antibiotic resistance (Katzif et al., 2003; Rowan, 1999; Rickard et al., 2004). In S. aureus, high salt stress increases resistance to penicillin-based antibiotics (Rohrer et al., 2003; Chambers & Hackbarth, 1987; Matthews & Stewart, 1984), represses the expression of virulence determinants (Chan & Foster, 1998) and affects cell morphology (Vijaranakul et al., 1995). Uniquely, S. aureus tolerates a wide range of salt concentrations on human skin, in foods or in human habitats by regulating cytoplasmic through the accumulation of L-proline, choline, taurine and betaine (Eriksen et al., 1995; Graham & Wilkinson, 1992; Otto, 2010). Betaine is the most effective osmolyte that can be imported from the environment, or it can be synthesized from acquired choline by the choline-conversion pathway enzymes in all kingdoms of life (Roessler & Muller, 2001; Sleator & Hill, 2002; Lamark et al., 1991; Kapfhammer et al., 2005; Cánovas et al., 2000; Craig, 2004; Mendum & Smith, 2002; Graham & Wilkinson, 1992; Gill et al., 2005; Gadda & McAllister-Wilkins, 2003).
Human tissues are rich sources of choline and betaine that can easily be depleted by colonizing and invading pathogenic bacteria (Ueland, 2011). The choline-conversion pathway of pathogenic bacteria represents a potential target for inhibiting or attenuating bacterial growth. Choline uptake and its oxidation to betaine is necessary for the survival of Pseudomonas aeruginosa in the mouse lung infection model (Wargo, 2013). Choline induces the expression of cudA and cudB (Rosenstein et al., 1999), which encode betaine aldehyde dehydrogenase (BADH) and choline dehydrogenase, respectively. Choline inhibits the growth of a cudA-deficient Staphylococcus xylosus strain. Similar effects of choline have been observed in Bacillus subtilis (Boch et al., 1996). In S. aureus, peak choline-transport activity appears to occur at a lower salt concentration than that of betaine transport. Thus, tolerance to a further salt increase would be determined by the influx of betaine, or its production from accumulated choline through the intermediate toxic product betaine aldehyde, and blocking further choline uptake by products of its oxidation (Kaenjak et al., 1993; Bae et al., 1993).
BADHs are a group of enzymes from the aldehyde dehydrogenase (ALDH) superfamily (Jackson et al., 2011) that primarily catalyze the oxidation of betaine aldehyde (BA) to betaine; some BADHs also utilize other substrates (Muñoz-Clares et al., 2010; Fitzgerald et al., 2009). In spite of varied substrate specificities, the generally accepted catalytic mechanism of the nicotinamide adenine dinucleotide (phosphate) [NAD(P)+]-dependent BADH/ALDH includes four steps (Feldman & Weiner, 1972). The first step is the formation of a covalent tetrahedral hemithioacetal–enzyme complex. Cofactor binding repositions a conserved catalytic cysteine for nucleophilic attack on the carbonyl of an aldehyde and the adjacent conserved glutamate residue deprotonates the Secondly, a covalent thioester intermediate is generated after a proton is transferred from the first intermediate to oxidized NAD(P)+. The third step includes the release of the reduced cofactor, allowing a nucleophilic water to attack the thioester to generate a second tetrahedral intermediate. Finally, an acid product leaves the active site and the cycle can repeat again. BADHs resemble ALDH in structure and are composed of a Rossmann-fold NAD(P)-binding domain, a catalytic (substrate-binding) domain and an (bridging) domain (Muñoz-Clares et al., 2010). Although BADHs have been characterized in Escherichia coli (EcBADH; PDB entries 1wnb and 1wnd; Falkenberg & Strøm, 1990; Gruez et al., 2004), B. subtilis (Boch et al., 1997), Halomonas elongata DSM 3043 (Cánovas et al., 2000), Pseudoalteromonas atlantica T6c (PDB entry 3k2w; New York SGX Research Center for Structural Genomics, unpublished work), Agrobacterium tumefaciens (AtBADH; PDB entry 3r31; New York Structural Genomics Research Consortium, unpublished work), P. aeruginosa (PaBADH; PDB entries 2wme, 2wox, 2xdr and 3zqa; González-Segura et al., 2009; Díaz-Sánchez et al., 2011; A. G. Díaz-Sánchez, L. González-Segura, E. Rudiño-Piñera, A. Lira-Rocha, A. Torres-Larios & R. A. Muñoz-Clares, unpublished work) and in eukaryotic organisms such as Gadus morhua (GmBADH; PDB entries 1a4s and 1bpw; Johansson et al., 1998), Pisum sativum (PsBADH; PDB entries 3iwk and 3imj; Tylichová et al., 2010), Spinacia oleracae (SoBADH; PDB entry 4a0m; Díaz-Sánchez et al., 2012) and Solanum lycopersicum (SlBADH; PDB entries 4i8p, 4i9b and 4i8q; Kopečny et al., 2013), questions remain about the molecular mechanism of action of BADH.
The sequenced genome of the early MRSA COL isolate revealed the presence of genes encoding osmoprotectant transport systems and choline-conversion pathway enzymes (Gill et al., 2005). Although osmotic stress response in S. aureus may involve alternative pathways (Tsai et al., 2011), the putative S. aureus BADH (SaBADH) may be a key contributing factor to this process. Initial structural analysis of SaBADH provided a platform for in-depth site-directed mutagenesis studies, which identified residues crucial to function and substrate inhibition, and these have been published elsewhere (Chen et al., 2014). The aim of this study was to provide essential insights into the structure and function of SaBADH. Our initial kinetic and preliminary surface plasmon resonance (SPR) spectroscopy data revealed temperature, pH and buffer effects on the dehydrogenase activity, stability and NAD+/NADH affinity of SaBADH. Among the previously functionally characterized SaBADH mutants (Chen et al., 2014), the Gly234Ser (G234S) mutant, G234S-SaBADH, had a higher affinity for NAD+ and decreased substrate inhibition, suggesting the existence of a structural and functional interaction between the NAD-binding and substrate-binding sites (Chen et al., 2014). Thus, this mutant was of particular interest and its in the apo and holo forms provides key atomic details on how the G234S substitution affects NAD+ binding. The structures of wild-type SaBADH and G234S-SaBADH purified and crystallized with β-mercaptoethanol (BME) reveal that the catalytic Cys289 is oxidized and this chemical modification may affect the affinity of SaBADH for its natural ligands. To maximize the structural resemblance of SaBADH to its native apo and holo states, we determined structures of the enzyme in the absence of BME. Comparison of the BME-free structures with those in the presence of BME highlight some interesting features that provide further understanding of the catalytic and inhibitory potential of SaBADH.
2. Materials and methods
2.1. Expression and purification of SaBADH and G234S-SaBADH
SaBADH was cloned into the pMCSG7 vector and expressed in E. coli BL21(DE3)/pMAGIC cells. The G234S mutation was introduced using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, California, USA) and the construct was cloned into the p15TV-LIC vector for expression. For each construct, E. coli cells harboring the expression plasmid were grown to an OD600 of 0.8 at 310 K with aeration at 200 rev min−1, chilled to 289 K and induced with 1 mM IPTG overnight. Cells were collected (6118g, 277 K) and lysed by sonication on ice in 10 mM Tris–HCl pH 8.3 buffer, 500 mM NaCl, in the presence of 5 mM BME (buffer A) [SaBADHBME(+) and G234S-SaBADHBME(+)] or in the presence of 0.5 mM tris(2-carboxyethyl)phosphine (TCEP) (buffer B) [SaBADHBME(−) and G234S-SaBADHBME(−)]. The proteins were purified using an Ni–NTA column (GE Healthcare, Piscataway, New Jersey, USA) and a Superdex 200 column (pre-equilibrated with either buffer A or B; GE Healthcare) at 277 K. The purity of the proteins was assayed by SDS–PAGE. The proteins were stored at 193 K.
2.2. Enzyme kinetics of SaBADH
The dehydrogenase activity of SaBADH was determined at 303 K by measuring the continuous absorbance increase of NADH at 340 nm (∊ = 6.22 mM−1 cm−1). The optimal catalytic pH was determined using 0.15 mM betaine aldehyde and 1 mM NAD+ in various buffers at 100 mM: 2-(N-morpholino)ethanesulfonic acid (MES; pH 5.5–6.5), potassium phosphate (pH 7.0–8.0) and N-cyclohexyl-2-aminoethanesulfonic acid (CHES; pH 8.5–10.0). Kinetic parameters were determined with various concentrations of one substrate in the presence of a saturated or subinhibitory concentration of the second substrate in 100 mM potassium phosphate buffer pH 8.0 and were calculated from the initial reaction rates using (1) or (2) with GraphPad Prism v.5.02 (GraphPad Software, San Diego, California, USA),
where [S] is the concentration of the varied substrate, Km is the Michaelis–Menten constant of the varied substrate and Ki is the dissociation constant of the varied substrate. One unit (U) of corresponds to the release of 1 µmol of NADH in 1 min. The effect of increasing the on betaine aldehyde dehydrogenase activity was tested in the presence of 0.0–2.5 M NaCl/KCl with 5 mM NAD+, 1 mM betaine aldehyde and 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer pH 8.0.
2.3. SPR studies of SaBADH
SaBADH was studied by SPR using Biacore S51 and 4000 optical biosensors (GE Healthcare). SaBADH (in buffer A at 22 mg ml−1) was immobilized (0.4 mg ml−1 in 10 mM sodium acetate buffer pH 5.0) on a CM5 sensor chip (GE Healthcare) using the standard amino-coupling method. Initially, 2 mM NAD+/NADH (using twofold dilution series; each concentration was tested three times) were probed for interactions with immobilized protein in 10 mM phosphate-buffered saline (PBS) buffer pH 7.0 containing 0.1% Brij-35 and 5 mM DTT at 277 K. This test revealed a fivefold higher affinity for NADH and thus all further SPR measurements were performed with NADH. The short-term (∼6 h) pH-dependent (pH range 6.0–8.0 in increments of 0.25) strength of the NADH–SaBADH interaction was analyzed using an SaBADH chip from the initial test and 333 µM NADH (threefold dilution series; each concentration was measured twice) at 277 K. The long-term test within the pH range 5.0–8.0 (in increments of 1.0) was conducted with 2 mM NADH (threefold dilution series; each concentration was measured twice) over 2 d starting with freshly immobilized SaBADH at 298 K. The pH dependence of NADH binding to SaBADH was compared with that of adenosine diphosphate (ADP; both ligands at 2 mM; pH range 5.0–8.0 at 298 K) using two-day-old immobilized SaBADH. Buffer-composition effects on the affinity of SaBADH for NADH were assayed in 10 mM buffers: (i) HEPES-buffered saline (HBS), (ii) potassium bisulfite (KBS) and (iii) 2-amino-2-hydroxymethyl-propane-1,3-diol (Tris)-buffered saline (TBS) at pH 7.0 and 298 K. Threefold dilution series starting at 2 mM NADH were used, with each concentration tested twice. Binding of betaine and BA (both 1 mM) to SaBADH was tested in 20 mM sodium phosphate buffer pH 7.0, 150 mM NaCl, 0.1% Brij-35, 2 mM DTT, 5% DMSO. The Salmonella typhimurium LT2 3-dehydroquinate dehydratase (AroD; Light et al., 2013) and its substrate dehydroquinic acid (DQA; 200 µM) were used as negative controls. Sodium malonate was probed for binding as a double-negative control for both AroD and SaBADH. Binding responses, measured as resonance units (RU), were double referenced and fitted with the Langmuir binding model using SCRUBBER2 available at https://www.biologic.com.au.
2.4. with multi-angle laser-light scattering (SEC-MALS)
SaBADHBME(+) was run on a Superdex 200 10/300 GL column (GE Healthcare) to estimate its molecular mass and state as described previously (Halavaty et al., 2012). SaBADHBME(+) (2 mg ml−1) was run in 10 mM Tris–HCl pH 8.3, 500 mM NaCl, 5 mM BME on a the column pre-equilibrated with the same buffer at a flow rate of 0.4 ml min−1 at 295 K. Bovine serum albumin (BSA; Sigma–Aldrich, St Louis, Missouri, USA) was used as a control protein. The molecular weights of the proteins were determined using the ASTRA software (Wyatt Technology Europe, Dernbach, Germany).
2.5. Dynamic (DLS)
All solutions were centrifuged and filtered prior to DLS analysis of SaBADHBME(−). A Zetasizer Nano S instrument (Malvern Instruments Inc., Westborough, Massachusetts, USA) and Zetasizer software 7.01 were used to perform measurements and determine the Z-average hydrodynamic radius (Rh), polydispersity index (PdI) and molecular weight (MW) using a globular polymer model. Data were acquired (ten acquisitions of 5 s each for each of the SaBADH concentrations) at 298 K using auto-attenuated He–Ne laser power (wavelength 663 nm) and a solvent of 1.33. SaBADH was tested at 10, 20, 30, 50, 80 and 100 µM in 10 mM Tris–HCl buffer pH 8.3, 0.5 mM TCEP and supplemented with 0.0, 0.5, 1.0, 1.5, 2.0 or 2.5 M NaCl or KCl. The analyzed data are an average of triplicate measurements over all concentrations of NaCl or KCl.
2.6. Crystallization of SaBADH and G234S-SaBADH
Proteins were crystallized using the sitting-drop vapor-diffusion technique, a Phoenix protein crystallization robot (Art Robbins Instruments, Sunnyvale, California, USA) and crystallization screens from Qiagen (Valencia, California, USA) at 295 K. Apo SaBADHBME(+) (at 7.4 mg ml−1) and apo SaBADHBME(−) (at 7.0 mg ml−1) were crystallizaed using a condition from The JCSG+ Suite consisting of 200 mM MgCl2, 100 mM Tris pH 8.5, 20%(w/v) PEG 8000. Crystals of apo SaBADHBME(+) with a modeled PEG molecule at the NAD- and substrate-binding sites [apo SaBADHBME(+)PEG] was obtained from a condition from The Classics II Suite consisting of 100 mM citric acid pH 3.5, 25%(w/v) PEG 3350. NAD–SaBADHBME(+) (at 7.4 mg ml−1 in 10 mM Tris–HCl pH 8.3, 250 mM NaCl, 5 mM BME plus 2 mM NAD+) was crystallized using a condition from The PEGs II Suite consisting of 200 mM sodium acetate, 100 mM Tris pH 8.5, 30%(w/v) PEG 4000. NAD–SaBADHBME(−) and NAD–G234S-SaBADHBME(−) (both at 7.0 mg ml−1 plus 2 mM NAD+) were crystallized using a condition from The JCSG+ Suite consisting of 100 mM potassium thiocyanate, 30%(w/v) PEG 2000 MME and a condition from The Classics II Suite consisting of 200 mM ammonium acetate, 100 mM Tris pH 8.5, 25%(w/v) PEG 3350, respectively. Apo G234S-SaBADHBME(−) (7.0 mg ml−1) and apo G234S-SaBADHBME(+) (at 7.3 mg ml−1) were crystallized using conditions from The PACT Suite consisting of 100 mM sodium propionate, sodium cacodylate and bis-tris propane (PCB) buffer pH 8.0, 25%(w/v) PEG 1500 and 100 mM succinic acid, sodium dihydrogen phosphate and glycine (SPG) buffer pH 8.0, 25%(w/v) PEG 1500, respectively. Crystals were soaked in the respective crystallization solutions for cryoprotection and flash-cooled in liquid nitrogen prior to X-ray data collection.
2.7. X-ray data collection, and validation
X-ray diffraction data were collected on beamlines 21-ID-F, 21-ID-G and 21-ID-D at the Life Science Collaborative Access Team (LS-CAT), Advanced Photon Source (APS), Argonne National Laboratory (ANL) (Tables 1 and 2). Data sets were processed with HKL-2000 (Otwinowski & Minor, 1997) and HKL-3000 (Minor et al., 2006). The of apo SaBADHBME(+) was determined by using a single chain of the human mitochondrial ALDH (PDB entry 1cw3; Ni et al., 1999) as a model and Phaser (McCoy et al., 2007) from the CCP4 package (Winn et al., 2011). The initial structure solution was rebuilt with ARP/wARP (Morris et al., 2003), manually modified in Coot (Emsley & Cowtan, 2004; Emsley et al., 2010) and refined with REFMAC v.5.7 (Murshudov et al., 2011). The other SaBADH and G234S-SaBADH crystal structures were determined by using the apo SaBADHBME(+) structure (PDB entry 4mpb) as a model. Translation–libration–screw (TLS) groups were obtained from the TLS Motion Determination (TLSMD) server (Painter & Merritt, 2006; https://skuld.bmsc.washington.edu/~tlsmd/) and introduced at the final stages of The quality of the structures was checked with the PDB validation server (https://deposit.pdb.org/validate/) and MolProbity (Chen et al., 2010; Davis et al., 2007; https://molprobity.biochem.duke.edu/). Diffraction images for the deposited structures are available at the Center for Structural Genomics of Infectious Diseases (CSGID) website (https://www.csgid.org/csgid/pages/home). The pairwise structural alignments were produced with the DaliLite server (Holm & Park, 2000; https://www.ebi.ac.uk/Tools/structure/dalilite/). The total buried surface area of the SaBADH assemblies was determined using the Protein Interfaces, Surfaces and Assemblies (PISA) service at the European Bioinformatics Institute (https://www.ebi.ac.uk/pdbe/prot_int/pistart.html; Krissinel & Henrick, 2007). Structural figures were generated with PyMOL (Schrödinger) and LigPlot+ v.1.4 (Laskowski & Swindells, 2011). Data-collection and structure-determination statistics are given in Table 1 for SaBADH and in Table 2 for G234S-SaBADH. The coordination geometries of modeled Na+, K+ and Mg2+ were validated with the CheckMyMetal (CMM) server (https://csgid.org/csgid/metal_sites/; Zheng et al., 2014). The identity of K+ was also confirmed by calculating an anomalous difference Fourier map.
|
|
3. Results
3.1. Enzymatic activity of SaBADH
Based on its sequence, the uncharacterized protein SACOL2628 from S. aureus was annotated as a BADH (SaBADH; UniProtKB entry Q5HCU0). The purified recombinant protein was highly specific for BA (Fig. 1) and showed negligible activity against other aldehyde substrates (Chen et al., 2014). SaBADH was also active with NAD(P)+, but the NAD-supported activity was at least ten times higher (Fig. 1, Table 3). The protein exhibited maximal activity at 500 mM NaCl/KCl and pH 8.0 and was fairly resistant to increasing (Fig. 1). SaBADH had negligibly slower kinetics in the presence of NAD+/K+ versus NAD+/Na+ (Fig. 1b), suggesting a functional preference for sodium. SaBADH was strongly inhibited by BA at concentrations of higher than 0.15 mM (Fig. 1d, Table 3), similarly to other BADHs (Velasco-García et al., 1999, 2000; Falkenberg & Strøm, 1990; Valenzuela-Soto & Muñoz-Clares, 1994; Boch et al., 1997). Detailed kinetic and inhibition studies of SaBADH have been published elsewhere (Chen et al., 2014).
|
3.2. SPR: SaBADH binds NAD+(H) in a pH-dependent manner
NADH was chosen as an indicator of specific binding because of its higher affinity for SaBADHBME(+) (Kd = 4.50 µM) versus NAD+ (Kd = 19.30 µM) (Fig. 2a) at pH 7.0. The same immobilized SaBADH was further assayed to determine the strength of the NADH–SaBADH interactions in a 6 h pH-dependent experiment at 277 K (Fig. 2b). From this experiment, a Kd value of 11.4 µM was obtained at pH 7.0, suggesting that the Kd differences may be attributed to variations in the experimental setups (see §2). The Kd for NADH at 298 K is higher than at 277 K at pH 7.0 (Figs. 2a and 2c), while no differences in the NADH binding were detected at pH 5.0, 6.0 and 7.0 with freshly made and two-day-old SaBADH surfaces at 298 K. However, a slight decrease in RU was observed at pH 8.0 with a two-day-old chip (not shown). Subjecting freshly immobilized SaBADH (tested with 1 mM NADH) to a 12 h stability evaluation at pH 8.0, we observed a ∼10 RU decrease from the zero-hour measurement (Fig. 3a, inset in the pH 8.0 graph). SaBADH and the S. typhimurium LT2 3-dehydroquinate dehydratase AroD interacted with sodium malonate (double-negative control; data not shown) nonselectively, while each of the proteins selectively responded to its natural ligand, NADH and DQA, respectively (Fig. 2c). The two enzymes had very weak affinity or no affinity for both 1 mM BA and betaine, as indicated by comparable low-level to noise-level RU signals, respectively (Fig. 2d). The pH-dependent strength of the NADH–SaBADH interaction was further compared with that between ADP and SaBADH (Fig. 3b). An acidic pH favored the ADP–SaBADH interaction (Fig. 4d), while NADH bound more strongly at pH 7.0 and more weakly at pH 8.0 (Fig. 3a). A moderate decrease in the NADH affinity was observed in the HEPES buffer and was likely to be caused by HEPES binding at the NAD-binding site (Fig. 3c), as has been observed with other proteins that bind nucleotide-based ligands (Majorek et al., 2014).
3.3. of wild-type SaBADH and G234S-SaBADH
We previously showed (Chen et al., 2014) that the substitution of Gly234, which is located in the NAD-binding area, by a serine residue increased the affinity of SaBADH for NAD+ and made the mutant more active than the wild type. The mutation also reduced the substrate inhibition. To fully understand the kinetic and inhibition mechanisms of G234S-SaBADH, we determined its crystal structures in apo and holo forms and in the presence/absence of BME and compared them with the wild-type structures.
All eight structures of SaBADH are similar to each other (r.m.s.d. of 0.2–0.8 Å over 496 Cα atoms) and the homologous ALDH/BADH (Fig. 4a). DALI (Holm & Rosenström, 2010) analysis found a putative ALDH from Burkholderia cenocepacia (PDB entry 4o6r; Seattle Structural Genomics Center for Infectious Disease, unpublished work) to be the closest structural homolog of SaBADH (Z-score of 59.6; r.m.s.d. of 1.3 Å; 38% sequence homology).
Consistent with the high overall similarity, obvious differences between the eight SaBADH structures are confined to residues Ala212–Glu217 (helix αF) and Val288–Ser290 (insets in Fig. 4a). The first peptide stretch adopts a helical conformation extending helix αF in the presence of NAD+ and interacts with the adenine ring of the cofactor. Although this segment is unwound in apo SaBADHBME(+/−), it forms a similar helix turn in apo G234S-SaBADHBME(+/−) and apo SaBADHBME(+)PEG. NAD+ binding results in displacement of the Cα atoms of the second area by ∼1.6–1.9 Å. However, in apo G234S-SaBADHBME(−) and apo SaBADHBME(+)PEG Val288–Ser290 is also repositioned in an NAD-dependent manner.
In the crystal, SaBADH forms a tetramer (∼21 400 Å2 buried surface area) that is composed of two dimers with ∼7900 Å2 buried surface area each (Fig. 4b). Hydrogen-bond and van der Waals interactions stabilize the tetramer. SEC-MALS analysis revealed two SaBADH peaks (theoretical monomer mass of 57 360.7 Da with the purification tag) with apparent molecular masses of ∼60 and ∼215 kDa, approximately corresponding to a monomer and tetramer, respectively (Fig. 4c). DLS analysis was performed to assess the state of SaBADH in the presence of 0.5–2.5 M NaCl/KCl. In the absence of each salt, SaBADH appears to be predominantly dimeric, with an estimated molecular mass of 168.1 ± 0.2 kDa (Rh of 5.32 ± 0.27 nm and PdI of 0.25 ± 0.03). An average Rh of 6.58 ± 1.47 nm (PdI of 0.23 ± 0.14) with an estimated molecular mass of 279.0 ± 8.7 kDa and an average Rh of 5.27 ± 0.65 nm (PdI of 0.14 ± 0.08) and molecular mass of 164.5 ± 1.2 kDa were obtained for all tested NaCl and KCl concentrations, respectively. Compared with the results obtained with no added salt, SaBADH exhibited a higher activity at both 500 mM NaCl and 500 mM KCl, at which the enzyme has an average Rh of 5.55 ± 0.50 nm (molecular mass of 185.6 ± 0.7 kDa and PdI of 0.17 ± 0.07) and an average Rh of 5.05 ± 0.31 nm (molecular mass of 148.8 ± 0.2 kDa and PdI of 0.10 ± 0.06), respectively. Thus, the SEC-MALS and DLS data are consistent with the showing that the enzyme is predominantly tetrameric in the presence of NaCl, while more of the SaBADH is dimeric in the presence of KCl.
3.4. The NAD-binding mode in SaBADH and G234S-SaBADH
NAD+ makes similar interactions with SaBADH and G234S-SaBADH (Supplementary Figs. S1a, S1b and S1c); PROPKA (Bas et al., 2008; Li et al., 2005) was used to estimate the pKa values of the residues within the NAD-binding and substrate-binding sites in the presence/absence of NAD+ (Supplementary Table S1). A positively charged surface of the NAD-binding site accommodates the adenosine monophosphate (AMP) moiety of the cofactor (Fig. 4d). The adenine ring is positioned in a cleft between helix αF and helix αG (residues Gly236–Ile241), while the ribose of AMP and the pyrophosphate group are solvent-oriented (Fig. 4a). The nicotinamide nucleotide (NMN) moiety is turned towards a negatively charged pocket in which the catalytic Cys289 is located (Figs. 4a and 4d). SaBADHBME(+/−) binds NAD+ in an orientation similar to the `hydrolysis' conformation (Muñoz-Clares et al., 2010) of the cofactor. Two alternative NAD+ conformations that differ in the orientation of the nicotinamide ring were modeled in NAD–SaBADHBME(−) to interpret the additional electron density (Figs. 5a and 5b). One of these NAD+ conformations aligns well with that in NAD–SaBADHBME(+). In NAD–G234S-SaBADHBME(−), the dinucleotide is in the `hydride-transfer' position (Muñoz-Clares et al., 2010), in which the amide group of NMN displaces the γ-carboxyl group of the catalytic base Glu255 towards its single `intermediate' conformation. The C4N atom of the cofactor is ∼2.5 Å from the Sγ atom of the `attacking' rotamer (González-Segura et al., 2009) of Cys289 (Fig. 5c). The wild-type apo and holo SaBADH structures had Glu255 in the `inside' and/or `intermediate' but not the `outside' conformations [as, for example, observed in human ALDH2; PDB entries 1zum (Larson et al., 2005) and 2onp (Larson et al., 2007)]. Structural comparison of all SaBADH structures revealed that the Leu256-Gly257 peptide bond may undergo a conformational switch to secure the `hydride-transfer' position of NAD+ or support the `inside' position (González-Segura et al., 2009) of Glu255 (Fig. 5c).
3.5. Substrate-binding site of SaBADH and G234S-SaBADH
The catalytic SaBADH were identified based on multiple sequence alignment with other BADHs. In all SaBADH structures the side chain of Cys289 adopts two alternative conformations denoted `resting' and `attacking' (González-Segura et al., 2009), but NAD–G234S-SaBADHBME(−), apo G234S-SaBADHBME(+) and NAD–SaBADHBME(+) only have the `attacking' rotamer (Fig. 5d). All (G234S-)SaBADHBME(+) structures have the `attacking' conformer oxidized with BME, while both Cys289 conformers of apo SaBADHBME(+)PEG are BME-modified. Bulky electron density at the Sγ atom in NAD–SaBADHBME(+) (chains B, C, E, G and H) was interpreted as two alternative conformations of the BME–Cys289 adduct. The hydroxyl group of BME interacts with the Asn157 side chain and/or a water molecule. Both Cys289 rotamers in apo G234S-SaBADHBME(−) were modeled as cysteine-S-dioxide to explain the outsized electron density at the Sγ atom (Fig. 5d).
Cys289 and the catalytic base Glu255 ofSuperposition of all eight SaBADH structures revealed additional residues close to Cys289, Glu255 and the NMN-binding and substrate-binding areas for which the conformations varied depending on whether (G234S-)SaBADH was in the apo or holo form (Fig. 5c). Noticeable side-chain motions of Tyr158 and Tyr450 in apo G234S-SaBADHBME(−), NAD–G234S-SaBADHBME(−) and apo SaBADHBME(+)PEG (Fig. 5c) may be functionally important for BA binding. Asn157 and Gln162 exhibited comparable smaller side-chain movements that may facilitate association/release of the cofactor/substrate/product (Fig. 5c and Supplementary Fig. S1b).
3.6. Cation-binding sites in SaBADH
Fig. 6 shows binding sites for Na+, K+ and Mg2+ at the dimerization interface of the protein and in the vicinity of the NAD-binding site. Binding of cations at similar sites have been reported previously (Muñoz-Clares et al., 2010) and were shown to activate BADH/ALDH through facilitation of NAD(P)+ association and to affect the tertiary and quaternary structures of the enzymes (Falkenberg & Strøm, 1990; Valenzuela-Soto & Muñoz-Clares, 1994; Muñoz-Clares et al., 2010; Velasco-García et al., 1999; Valenzuela-Soto et al., 2003; González-Segura et al., 2013; Garza-Ramos et al., 2013). Mg2+ (Fig. 6b), Na+ (Fig. 6c) and K+ (Fig. 6f) bind at the dimerization interface and have one ligand in common, Val249; however, their modeled positions differ owing to their different coordination spheres. Alignment of the corresponding SaBADH structures revealed that the aforementioned K+ and Na+ ions are just ∼0.8 Å apart, while Mg2+ is ∼2.4 and ∼2.7 Å from Na+ and K+, respectively. NAD–SaBADHBME(−) has an additional K+-binding site (Fig. 6g) that is 6.1 Å away from that shown in Fig. 6(f). The modeled positions of Na+ (Fig. 6d) and K+ (Fig. 6e) are just ∼0.3 Å apart and are located near the NAD+-binding site between the NAD-binding domain and the catalytic domain.
4. Discussion
4.1. The annotated SaBADH is a functional BADH
The putative S. aureus betaine aldehyde dehydrogenase enzyme SACOL2628 is indeed a functional BADH that utilizes NAD+ and BA as the primary cofactor and substrate, respectively (Fig. 1, Table 3). The activity is inhibited by high concentrations of BA. Kinetic data also show that SaBADH is slightly more active in the presence of Na+ than in the presence of K+. DLS data suggest that Na+-induced tetramerization of SaBADH may account for the observed higher activity compared with SaBADH in the presence of K+. SaBADH has maximal activity at 500 mM NaCl or KCl, and a further increase in the may slightly reduce the activity by weakening the interactions required for NAD+ and BA binding without significantly affecting the state.
NAD+ and NADH bind SaBADH in a pH-dependent manner, with NADH having higher affinity for SaBADH at pH 7.0 and 277 K (Fig. 2a). Although the pH-dependence of NAD+ binding was not tested in SPR, SaBADH activity and its co-crystallization with NAD+ at pH 8.0 suggest that the oxidized form of the cofactor binds more strongly at the alkaline pH. As suggested by our previously published mutagenesis (Chen et al., 2014) and shown by the crystallographic data presented here, initial NAD+ binding causes structural changes within the substrate-binding pocket that facilitate BA binding. Thus, the weak binding of BA to immobilized apo SaBADH (Fig. 2d) may be explained by the lack of these structural changes. BME modification of Cys289 may further affect the affinity of BA for the enzyme (right inset in Fig. 4a, and Figs. 5c and 5d). Overall, we showed that immobilized SaBADH remained stable and binds its cofactor and substrate over 2 d of SPR analysis. The empirically derived Kd values, however, need further careful re-quantification, since SaBADH was tested in the presence of BME and DTT, which may affect the binding of NAD+/NADH and BA.
4.2. Structural–functional link between the NAD-binding and substrate-binding sites
The highly conserved residues of the cofactor-binding site govern the NAD+–SaBADH interactions similarly to other BADH/ALDHs (Figs. 4a and 7a and Supplementary Fig. S1). Comprehensive structural analysis of SaBADH elaborates on how NAD+ binding traps the enzyme in a conformational state that facilitates the catalysis.
Firstly, the adenine ring of NAD+ imposes structural changes on helix αF that were also observed in apo G234S-SaBADHBME(+/−) and apo SaBADHBME(+)PEG. Difference electron-density peaks around the Ala212–Glu215 segment of the helix of these apo structures suggest that this region might be flexible in general and that NAD+ binding selects or induces the favorable conformational state. The atoms of residues Ala212–Glu215 exhibit higher B factors than those of the adjacent residues.
Secondly, with NAD+ in either the `hydrolysis' or the `hydride-transfer' position, the Val288–Ser290 loop that bears the catalytic Cys289 is displaced from its apo position (Figs. 5a and 5c). As a result of this relocation, an internal cavity around Cys289 expands and can be utilized for proper positioning of BA (Fig. 7b). Oxidation of Cys289 to a sulfinic acid in apo G234S-SaBADHBME(−) and chemical mimicry of the PEG molecules in apo SaBADHBME(+)PEG at the NAD-binding and substrate-binding sites may prompt the loop to retreat (Figs. 4b and 5d). The Val288–Ser290 loop in apo G234S-SaBADHBME(−) and all NAD-bound SaBADH structures is structurally aligned with an equivalent Asp279–Thr281 loop in the apo/holo structures of the E. coli BADH YdcW (PDB entries 1wnd and 1wnb; Gruez et al., 2004). YdcW contains Ser225 instead of Gly234 (SaBADH) and its catalytic Cys280 is reduced. Thus, the G234S substitution in SaBADH may also contribute to the repositioning of the loop. A possible effect of the BME–Cys289 adduct on the loop repositioning in apo SaBADHBME(+)PEG is excluded because the loop is in the apo conformation in apo SaBADHBME(+).
Thirdly, the observed main-chain/side-chain flexibility of the active-site residues Asn157, Gln162, Glu255, Leu256 and Gly257 might facilitate cofactor and substrate binding (Fig. 5c and Supplementary Fig. S1).
Fourthly, the NAD-dependent repositioning of the Val288–Ser290 loop may also cause changes in the main-chain/side-chain torsional angles of Asp111, Tyr158, His448 and Tyr450 located near the substrate-binding site (Figs. 5c and 7a). Based on our structural analysis, we propose that Asp111 and His448 may assist in BA binding by, for example, stabilizing the side chains of Tyr158 and Tyr450, which would in turn precisely guide/position BA in the vicinity of Cys289. Although the two tyrosine residues showed modest dihedral angle variations in the presence of NAD+ and substrate-mimicking molecules (Figs. 5c and 5d), their rotational freedom may still be limited by the neighboring Pro159, Trp165, Pro449 and Trp456. Further, intermolecular interactions at the tetramerization interface could reduce the conformational freedom of the loop (residues Ile444–Tyr459) that contains Tyr450.
Thus, upon NAD+ binding structural changes at the cofactor-docking site are further transmitted to the BA-binding area, facilitating recognition and binding of the substrate within a distance suitable for nucleophilic attack by Cys289.
4.3. The NAD-binding mode in SaBADH
The BME–Cys289 adduct and the G234S mutation determine the NAD-binding mode in SaBADH. The adduct may mimic the intermediate enzyme–substrate complex and thus promote NAD+ binding in the `hydrolysis' position in NAD–SaBADHBME(+). With the reduced Cys289, the two `hydrolysis' positions were modeled in NAD–SaBADHBME(−), yet ambiguous electron density at the NAD-binding site may also indicate a mixture of the `hydrolysis' and `hydride-transfer' positions (Fig. 5b). Traces of in PEG-based crystallization conditions have been proposed to account for the dehydrogenase activity of human ALDH (PDB entry 1o00; Perez-Miller & Hurley, 2003). Since SaBADHBME(−) was purified and co-crystallized with NAD+ from PEG at a pH of ∼8.0, at which it exhibited maximum activity (Fig. 1a), it is possible that SaBADHBME(−) was turning over in the crystal. The lack of a serine residue at position 234, which stabilizes the `hydride-transfer' position of NAD+ in NAD–G234S-SaBADHBME(−), may also account for the observed flexibility of NAD+ in NAD–SaBADHBME(−). When the NAD–G234S-SaBADHBME(−) and NAD–SaBADHBME(−) structures were superimposed, the NAD+ `hydride-transfer' conformer of the former structure fitted the aforementioned uncertain electron density of the latter structure. An alternative interpretation is that NAD+ and SaBADHBME(−) may form a covalent adduct similar to that between NADP+ and PaBADH (PDB entry 2wox; Díaz-Sánchez et al., 2011). However, such a covalent adduct could not explain the observed NAD+ electron-density peaks. Furthermore, the conformations of Cys289 and Glu255 of NAD–SaBADHBME(−) would not allow dinucleotide–Cys adduct formation. Thus, BME oxidation of Cys289 and the G234S mutation helped to trap the `hydrolysis' and `hydride-transfer' positions of the cofactor, respectively, allowing analysis of these binding modes in SaBADH.
4.4. Preference for NAD+ over NADP+ in SaBADH
BADHs efficiently use NAD+/NADP+ (Mori et al., 1992; Velasco-García et al., 2000), while SaBADH prefers NAD+ (Table 3). Comparison of the NADP–PaBADH (PDB entry 2wme; González-Segura et al., 2009) and NAD–SaBADH structures suggested a rationale for preferential NAD+ binding in SaBADH. In NADP–PaBADH, Lys176, Ser178, Glu179, Gly207 and Gly209 (Lys180, Ser182, Glu183, Gly211 and Gly213 in SaBADH) coordinate the 2′-phosphate group (2′-P) of NADP+ (Fig. 7c and Supplementary Fig. S1d). The 2′-P displaces the side chain of Glu179 (Glu183 in SaBADH) and makes a salt bridge with Arg40 (Glu42 in SaBADH). Similar contacts and rearrangements within SaBADH would be expected in the presence of NADP+. However, sequence variations at the 2′-P docking area and metal-binding site ∼11 Å away from the 2′-P binding area may selectively favor the binding of one form of the cofactor over another. K+ (K+1493 in PaBADH) and Na+/K+ (SaBADH) (Figs. 6d, 6e and 7c) occupy the referred metal-binding site, yet their coordination geometries differ in the two structures. The hydroxyl group of Thr26 of PaBADH (Ile28 in SaBADH) binds K+1493, while a water molecule substitutes for the OH group of Thr26 in SaBADH. Differences in the metal-coordination spheres seem to influence the position of the Ser178–Val180 loop of PaBADH (residues Ser182–Ile184 in SaBADH), which is closer to the 2′-P binding site in PaBADH than in SaBADH (Fig. 7b and Supplementary Fig. S1d), hence making the 2′-P–PaBADH interactions stronger. Based on this observation, the weaker affinity of SaBADH for NADP+ may then be a consequence of the Thr26-to-Ile28 substitution and sequence variations within the 2′-P binding pocket.
5. Conclusions
The high S. aureus can be handled by (i) the accumulation of the exogenous osmolyte betaine and (ii) its biosynthesis from choline. The second pathway generates a toxic BA intermediate that is oxidized by BADH to betaine. Increasing experimental evidence suggests an important role for BADHs in the survival of pathogenic bacteria, which in turn emphasizes the need for a detailed evaluation of the structure and function of the enzymes. We studied a putative BADH from an early MRSA COL isolate, denoted SaBADH, and showed that it is a functional NAD+-dependent BADH that utilizes BA as the primary substrate. The affinity of SaBADH for NAD+/NADH/BA depends on pH, temperature and buffer composition, although it was also affected by BME/DTT oxidation of the catalytic Cys289. The enzymatic activity is quite tolerant to high yet may be attenuated at high The solution data are supported by the structural analysis and emphasize the importance of the NAD+-driven structural rearrangements at the cofactor-binding and substrate-binding sites for enzymatic activity. The Val288–Ser290 loop that contains the catalytic Cys289 repositions in the presence of NAD+, creating room for the nucleophilic reaction. While NAD+ is bound, Tyr158 and Try450 at the substrate-binding site may play the role of active-site `gatekeepers' and help to position the substrate at a distance suitable for nucleophilic attack. Overall, extensive structural analysis and preliminary ligand-binding data support our previously published comprehensive structure-based mutagenesis data on the ordered bi-bi kinetic mechanism, substrate inhibition and existence of a structural–functional link between the NAD-binding and substrate-binding sites (Chen et al., 2014).
burden inSupporting information
PDB references: betaine aldehyde dehydrogenase, 4mpb; complex with NAD+, 4mpy; complex with NAD+ with BME-free Cys289, 4nea; with BME-free Cys289, 4nu9; with BME-modified Cys289 and PEG molecule in active site, 4qto; G234S mutant, in complex with NAD+ with BME-free Cys289, 4qn2; G234S mutant, with BME-modified Cys289, 4q92; G234S mutant, with BME-free sulfinic acid form of Cys289, 4qje
Supporting Information. DOI: https://doi.org/10.1107/S1399004715004228/mn5083sup2.pdf
Acknowledgements
We acknowledge the staff of the LS-CAT Sector 21 for their assistance in data collection. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor for the support of this research program (Grant 085P1000817). Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-06CH11357. This work was also supported by the Samsung GRO-2012 grant (to AFY), the Government of Canada through Genome Canada, the Ontario Genomics Institute and Ontario Research Fund (2009-OGI-ABC-1405; ORF-GL2-01-004). We thank Drs Filippova and Light for critical reading of the manuscript. The SEC-MALS analysis was supported by Keck Biophysics Facility (Cancer Center Support Grant; NCI CA060553). The CSGID project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services under Contract Nos. HHSN272200700058C and HHSN272201200026C (to WFA).
References
Abboud, F. M. & Waisbren, B. A. (1959). AMA Arch. Intern. Med. 104, 226–233. CrossRef PubMed CAS Google Scholar
Archer, D. L. (1996). Trends Food Sci. Technol. 7, 91–95. CrossRef CAS Web of Science Google Scholar
Armand-Lefevre, L., Ruimy, R. & Andremont, A. (2005). Emerg. Infect. Dis. 11, 711–714. Web of Science PubMed Google Scholar
Bae, J.-H., Anderson, S. H. & Miller, K. J. (1993). Appl. Environ. Microbiol. 59, 2734–2736. CAS PubMed Web of Science Google Scholar
Bas, D. C., Rogers, D. M. & Jensen, J. H. (2008). Proteins, 73, 765–783. Web of Science CrossRef PubMed CAS Google Scholar
Boch, J., Kempf, B., Schmid, R. & Bremer, E. (1996). J. Bacteriol. 178, 5121–5129. CAS PubMed Web of Science Google Scholar
Boch, J., Nau-Wagner, G., Kneip, S. & Bremer, E. (1997). Arch. Microbiol. 168, 282–289. CrossRef CAS PubMed Web of Science Google Scholar
Cánovas, D., Vargas, C., Kneip, S., Morón, M. J., Ventosa, A., Bremer, E. & Nieto, J. J. (2000). Microbiology, 146, 455–463. Web of Science PubMed Google Scholar
Chambers, H. F. & Hackbarth, C. J. (1987). Antimicrob. Agents Chemother. 31, 1982–1988. CrossRef CAS PubMed Google Scholar
Chan, P. F. & Foster, S. J. (1998). J. Bacteriol. 180, 6232–6241. Web of Science CAS PubMed Google Scholar
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. Web of Science CrossRef CAS IUCr Journals Google Scholar
Chen, C., Joo, J. C., Brown, G., Stolnikova, E., Halavaty, A. S., Savchenko, A., Anderson, W. F. & Yakunin, A. F. (2014). Appl. Environ. Microbiol. 80, 3992–4002. Web of Science CrossRef CAS PubMed Google Scholar
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W. & Carmeli, Y. (2006). Clin. Infect. Dis. 36, 53–59. Web of Science CrossRef Google Scholar
Craig, S. A. S. (2004). Am. J. Clin. Nutr. 80, 539–549. Web of Science PubMed CAS Google Scholar
Cuny, C., Friedrich, A., Kozytska, S., Layer, F., Nübel, U., Ohlsen, K., Strommenger, B., Walther, B., Wieler, L. & Witte, W. (2010). Int. J. Med. Microbiol. 300, 109–117. Web of Science CrossRef PubMed Google Scholar
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S. & Richardson, D. C. (2007). Nucleic Acids Res. 35, W375–383. Web of Science CrossRef PubMed Google Scholar
DeLeo, F. R. & Chambers, H. F. (2009). J. Clin. Invest. 119, 2464–2474. Web of Science CrossRef PubMed CAS Google Scholar
Díaz-Sánchez, Á. G., González-Segura, L., Mújica-Jiménez, C., Rudiño-Piñera, E., Montiel, C., Martínez-Castilla, L. P. & Muñoz-Clares, R. A. (2012). Plant Physiol. 158, 1570–1582. Web of Science PubMed Google Scholar
Díaz-Sánchez, Á. G., González-Segura, L., Rudiño-Piñera, E., Lira-Rocha, A., Torres-Larios, A. & Muñoz-Clares, R. A. (2011). Biochem. J. 439, 443–452. Web of Science PubMed Google Scholar
Eady, E. A. & Cove, J. H. (2003). Curr. Opin. Infect. Dis. 16, 103–124. CrossRef PubMed CAS Google Scholar
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Eriksen, N. H. R., Espersen, F., Rosdahl, V. T. & Jensen, K. (1995). Epidemiol. Infect. 115, 51–60. CrossRef CAS PubMed Google Scholar
Falkenberg, P. & Strøm, A. R. (1990). Biochim. Biophys. Acta, 1034, 253–259. CrossRef CAS PubMed Web of Science Google Scholar
Feldman, R. I. & Weiner, H. (1972). J. Biol. Chem. 247, 267–272. CAS PubMed Web of Science Google Scholar
Fitzgerald, T. L., Waters, D. L. E. & Henry, R. J. (2009). Plant Biol. 11, 119–130. Web of Science CrossRef PubMed CAS Google Scholar
Fluit, A. C. (2012). Clin. Microbiol. Infect. 18, 735–744. Web of Science CrossRef CAS PubMed Google Scholar
Gadda, G. & McAllister-Wilkins, E. E. (2003). Appl. Environ. Microbiol. 69, 2126–2132. Web of Science CrossRef PubMed Google Scholar
Garza-Ramos, G., Mújica-Jiménez, C. & Muñoz-Clares, R. A. (2013). PLoS One, 8, e54899. Web of Science PubMed Google Scholar
Gill, S. R. et al. (2005). J. Bacteriol. 187, 2426–2438. Web of Science CrossRef PubMed CAS Google Scholar
González-Segura, L., Riveros-Rosas, H., Díaz-Sánchez, Á. G., Julián-Sánchez, A. & Muñoz-Clares, R. A. (2013). Chem. Biol. Interact. 202, 41–50. Web of Science PubMed Google Scholar
González-Segura, L., Rudiño-Piñera, E., Muñoz-Clares, R. A. & Horjales, E. (2009). J. Mol. Biol. 385, 542–557. Web of Science PubMed Google Scholar
Graham, J. E. & Wilkinson, B. J. (1992). J. Bacteriol. 174, 2711–2716. PubMed CAS Web of Science Google Scholar
Gruez, A., Roig-Zamboni, W., Grisel, S., Salomoni, A., Valencia, C., Campanacci, V., Tegoni, M. & Cambillau, C. (2004). J. Mol. Biol. 343, 29–41. Web of Science CrossRef PubMed CAS Google Scholar
Halavaty, A. S., Borek, D., Tyson, G. H., Veesenmeyer, J. L., Shuvalova, L., Minasov, G., Otwinowski, Z., Hauser, A. R. & Anderson, W. F. (2012). PLoS One, 7, e49388. Web of Science CrossRef PubMed Google Scholar
Holm, L. & Park, J. (2000). Bioinformatics, 16, 566–567. Web of Science CrossRef PubMed CAS Google Scholar
Holm, L. & Rosenström, P. (2010). Nucleic Acids Res. 38, W545–W549. Web of Science CrossRef CAS PubMed Google Scholar
Jackson, B., Brocker, C., Thompson, D. C., Black, W., Vasiliou, K., Nebert, D. W. & Vasiliou, V. (2011). Hum. Genomics, 5, 283–303. CrossRef CAS PubMed Google Scholar
Jevons, M. P. (1961). BMJ, 1, 124–125. CrossRef Google Scholar
Johansson, K., Ramaswamy, S., Eklund, H., El-Ahmad, M., Hjelmqvist, L. & Jörnvall, H. (1998). Protein Sci. 7, 2106–2117. CrossRef CAS PubMed Google Scholar
Kaenjak, A., Graham, J. E. & Wilkinson, B. J. (1993). J. Bacteriol. 175, 2400–2406. CAS PubMed Web of Science Google Scholar
Kapfhammer, D., Karatan, E., Pflughoeft, K. J. & Watnick, P. I. (2005). Appl. Environ. Microbiol. 71, 3840–3847. Web of Science CrossRef PubMed CAS Google Scholar
Katzif, S., Danavall, D., Bowers, S., Balthazar, J. T. & Shafer, W. M. (2003). Infect. Immun. 71, 4304–4312. Web of Science CrossRef PubMed CAS Google Scholar
Kluytmans, J. A. (2010). Clin. Microbiol. Infect. 16, 11–15. Web of Science CrossRef CAS PubMed Google Scholar
Kopečny, D., Končitíková, R., Tylichová, M., Vigouroux, A., Moskalíková, H., Soural, M., Šebela, M. & Moréra, S. (2013). J. Biol. Chem. 288, 9491–9507. Web of Science PubMed Google Scholar
Krissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797. Web of Science CrossRef PubMed CAS Google Scholar
Lamark, T., Kaasen, I., Eshoo, M. W., Falkenberg, P., McDougall, J. & Strøm, A. R. (1991). Mol. Microbiol. 5, 1049–1064. CrossRef PubMed CAS Web of Science Google Scholar
Larson, H. N., Weiner, H. & Hurley, T. D. (2005). J. Biol. Chem. 280, 30550–30556. Web of Science CrossRef PubMed CAS Google Scholar
Larson, H. N., Zhou, J., Chen, Z., Stamler, J. S., Weiner, H. & Hurley, T. D. (2007). J. Biol. Chem. 282, 12940–12950. Web of Science CrossRef PubMed CAS Google Scholar
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). J. Appl. Cryst. 26, 283–291. CrossRef CAS Web of Science IUCr Journals Google Scholar
Laskowski, R. A. & Swindells, M. B. (2011). J. Chem. Inf. Model. 51, 2778–2786. Web of Science CrossRef CAS PubMed Google Scholar
Li, H., Robertson, A. D. & Jensen, J. H. (2005). Proteins, 61, 704–721. Web of Science CrossRef PubMed CAS Google Scholar
Light, S. H., Anderson, W. F. & Lavie, A. (2013). Protein Sci. 22, 418–424. Web of Science CrossRef CAS PubMed Google Scholar
Majorek, K. A., Kuhn, M. L., Chruszcz, M., Anderson, W. F. & Minor, W. (2014). Protein Sci. 23, 1359–1368. Web of Science CrossRef CAS PubMed Google Scholar
Matthews, P. R. & Stewart, P. R. (1984). FEMS Microbiool. Rev. 22, 161–166. CrossRef CAS Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
McDowell, D. A. (2004). Safety Assurance During Food Processing: Food Safety Assurance and Veterinary Public Health, edited by F. J. M. Smulders & J. D. Collins, pp. 243–265. Wageningen: Wageningen Academic Publishers. Google Scholar
McMahon, M. A., Xu, J., Moore, J. E., Blair, I. S. & McDowell, D. A. (2007). Appl. Environ. Microbiol. 73, 211–217. Web of Science CrossRef PubMed CAS Google Scholar
Mendum, M. L. & Smith, L. T. (2002). Appl. Environ. Microbiol. 68, 813–819. Web of Science CrossRef PubMed CAS Google Scholar
Minor, W., Cymborowski, M., Otwinowski, Z. & Chruszcz, M. (2006). Acta Cryst. D62, 859–866. Web of Science CrossRef CAS IUCr Journals Google Scholar
Moellering, R. C. Jr (2012). J. Antimicrob. Chemother. 67, 4–11. Web of Science CrossRef CAS PubMed Google Scholar
Mori, N., Yoshida, N. & Kitamoto, Y. (1992). J. Ferment. Bioeng. 73, 352–356. CrossRef CAS Web of Science Google Scholar
Morris, R. J., Perrakis, A. & Lamzin, V. S. (2003). Methods Enzymol. 374, 229–244. Web of Science CrossRef PubMed CAS Google Scholar
Muñoz-Clares, R. A., Díaz-Sánchez, Á. G., González-Segura, L. & Montiel, C. (2010). Arch. Biochem. Biophys. 493, 71–81. Web of Science PubMed Google Scholar
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Ni, L., Zhou, J., Weiner, H. & Hurley, T. D. (1999). Protein Sci. 8, 2784–2790. CrossRef PubMed CAS Google Scholar
Otto, M. (2010). Exp. Rev. Dermatol. 5, 183–195. CrossRef CAS Google Scholar
Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. CrossRef CAS PubMed Web of Science Google Scholar
Painter, J. & Merritt, E. A. (2006). Acta Cryst. D62, 439–450. Web of Science CrossRef CAS IUCr Journals Google Scholar
Pantosti, A. (2012). Front. Microbiol. 3, 127. Web of Science CrossRef PubMed Google Scholar
Paulsen, I. T., Firth, M. & Skurray, R. A. (1997). The Staphylococci in Human Disease, edited by K. B. Crossley & G. L. Archer, pp. 175–212. New York: Churchill Livingstone. Google Scholar
Perez-Miller, S. J. & Hurley, T. D. (2003). Biochemistry, 42, 7100–7109. Web of Science PubMed CAS Google Scholar
Rickard, A. H., Lindsay, S., Lockwood, G. B. & Gilbert, P. (2004). J. Appl. Microbiol. 97, 1063–1068. Web of Science CrossRef PubMed CAS Google Scholar
Roessler, M. & Muller, V. (2001). Environ. Microbiol. 3, 743–754. Web of Science CrossRef PubMed CAS Google Scholar
Rohrer, S., Maki, H. & Berger-Bächi, B. (2003). J. Med. Microbiol. 52, 605–607. Web of Science CrossRef PubMed Google Scholar
Rosenstein, R., Futter-Bryniok, D. & Götz, F. (1999). J. Bacteriol. 181, 2273–2278. Web of Science PubMed CAS Google Scholar
Rowan, N. J. (1999). Trends Food Sci. Technol. 10, 261–270. Web of Science CrossRef CAS Google Scholar
Scheffler, R. J., Colmer, S., Tynan, H., Demain, A. L. & Gullo, V. P. (2013). Appl. Microbiol. Biotechnol. 97, 969–978. Web of Science CrossRef CAS PubMed Google Scholar
Sleator, R. D. & Hill, C. (2002). FEMS Microbiool. Rev. 26, 49–71. Web of Science CrossRef CAS Google Scholar
Tsai, M., Ohniwa, R. L., Kato, Y., Takeshita, S. L., Ohta, T., Saito, S., Hayashi, H. & Morikawa, K. (2011). BMC Microbiol. 11, 13. Google Scholar
Tylichová, M., Kopečný, D., Moréra, S., Briozzo, P., Lenobel, R., Snégaroff, J. & Šebela, M. (2010). J. Mol. Biol. 396, 870–882. Web of Science PubMed Google Scholar
Ueland, P. M. (2011). J. Inherit. Metab. Dis. 34, 3–15. Web of Science CrossRef CAS PubMed Google Scholar
Valenzuela-Soto, E. M. & Muñoz-Clares, R. A. (1994). J. Plant Physiol. 143, 145–152. CAS Google Scholar
Valenzuela-Soto, E. M., Velasco-García, R., Mújica-Jiménez, C., Gaviria-González, L. & Muñoz-Clares, R. A. (2003). Chem. Biol. Interact. 143–144, 139–148. Web of Science PubMed CAS Google Scholar
Velasco-García, R., González-Segura, L. & Muñoz-Clares, R. A. (2000). Biochem. J. 352, 675–683. Web of Science PubMed Google Scholar
Velasco-García, R., Mújica-Jiménez, C., Mendoza-Hernández, G. & Muñoz-Clares, R. A. (1999). J. Bacteriol. 181, 1292–1300. Web of Science PubMed Google Scholar
Vijaranakul, U., Nadakavukaren, M. J., de Jonge, B. L., Wilkinson, B. J. & Jayaswal, R. K. (1995). J. Bacteriol. 177, 5116–5121. CAS PubMed Web of Science Google Scholar
Walsh, C. (1999). Science, 284, 442–443. Web of Science CrossRef PubMed CAS Google Scholar
Wargo, M. J. (2013). PLoS One, 8, e56850. Web of Science CrossRef PubMed Google Scholar
Wendlandt, S., Schwarz, S. & Silley, P. (2013). Annu. Rev. Food. Sci. Technol. 4, 117–139. Web of Science CrossRef CAS PubMed Google Scholar
Wenzel, R. P. (2004). N. Engl. J. Med. 351, 523–526. Web of Science CrossRef PubMed CAS Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Zheng, H., Chordia, M. D., Cooper, D. R., Chruszcz, M., Müller, P., Sheldrick, G. M. & Minor, W. (2014). Nature Protoc. 9, 156–170. Web of Science CrossRef CAS Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.